(Reuters) – Madrigal Pharmaceuticals Inc said on Monday a late-stage trial showed that its experimental drug helped reduce liver fat and certain lipids in patients with non-alcoholic steatohepatitis (NASH), an inflammatory disease of the liver. The drug resmetirom was found to be safe and well-tolerated when given in doses of…